Lung cancer screening in patients with previous malignancy: Is this cohort at increased risk for malignancy?

O’Dwyer, Elisabeth; Halpenny, Darragh; Ginsberg, Michelle S.

doi:10.1007/s00330-020-07026-x

Cited by 14 publications

(17 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indicator for Further Observation. 18F-FDG PET/CT detection confirmed criteria: the concentration of mediastinal pool was less than that of the lesion, lobulation sign and burr sign were present at the edge of the lesion, the lesion tissue showed air bronchial sign, thick-walled cavity, ground glass density shadow, etc., and vascular cluster sign and pleural depression sign were present around the lesion [12] Note. "+" means positive and "−" means negative.…”

Section: 3mentioning

confidence: 99%

The Efficacy of 18F-FDG PET/CT and Superparamagnetic Nanoferric Oxide MRI in the Diagnosis of Lung Cancer and the Value of 18F-FDG PET/CT in the Prediction of Lymph Node Metastasis

Yao

Zuo

Zhang

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

In China, lung cancer is one of the leading causes of death among residents. Early diagnosis is of great significance for early interventional treatment and prolonging survival. PET/CT uses positron radiopharmaceuticals to observe the physiological and biochemical changes of the drug and its metabolites in the body and finally diagnoses the disease. 18F-FDG is a commonly used imaging agent, but its short isotopic half-life limits clinical high-throughput testing. This study retrospectively analyzed the imaging material of 100 lung cancer patients pathologically confirmed. Patients with lymph node metastasis were classified into the LM group ( n = 30 cases), and those with no lymph node metastasis were classified into the NLM group ( n = 70 cases). The results showed that MRI of superparamagnetic nanoferric oxide was better than diagnosis of lung cancer by the 18F-FDG PET/CT and had a high predictive power for lymph node metastasis. These turned out to be high-value lung cancer diagnosis of superparamagnetic nanoferric oxide MRI and high-capacity lymph node metastasis prediction of 18F-FDG PET/CT, which were worthy of implementation.

show abstract

Section: 3mentioning

confidence: 99%

The Efficacy of 18F-FDG PET/CT and Superparamagnetic Nanoferric Oxide MRI in the Diagnosis of Lung Cancer and the Value of 18F-FDG PET/CT in the Prediction of Lymph Node Metastasis

Yao

Zuo

Zhang

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…For example, a recent retrospective study showed a rate of 6.4% for SPLC in patients with prior cancer. Nineteen percent of these patients had IPHNC with a rate of 6.7% for SPLC after IPHNC 3 . Another study showed that the standardized incidence of SPLC in patients with IPHNC far exceeded that of lung cancer in the control arm of the National Lung Screening Trial 4 .…”

Section: Introductionmentioning

confidence: 99%

“…2 In addition to these traditional risk factors, many studies have shown former history of cancer to be associated with development of second primary lung cancer (SPLC). 3,4 Of these primary cancers, initial primary head and neck cancer (IPHNC) is commonly associated with SPLC. 3,4 For example, a recent retrospective study showed a rate of 6.4% for SPLC in patients with prior cancer.…”

Section: Introductionmentioning

confidence: 99%

“…3,4 Of these primary cancers, initial primary head and neck cancer (IPHNC) is commonly associated with SPLC. 3,4 For example, a recent retrospective study showed a rate of 6.4% for SPLC in patients with prior cancer. Nineteen percent of these patients had IPHNC with a rate of 6.7% for SPLC after IPHNC.…”

Section: Introductionmentioning

confidence: 99%

“…Current NCCN guidelines base their recommendations for lung cancer screening on age and smoking history 2 . In addition to these traditional risk factors, many studies have shown former history of cancer to be associated with development of second primary lung cancer (SPLC) 3,4 . Of these primary cancers, initial primary head and neck cancer (IPHNC) is commonly associated with SPLC 3,4 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer

et al. 2022

View full text Add to dashboard Cite

Background: Initial primary head and neck cancer (IPHNC) is associated with second primary lung cancer (SPLC). We studied this association in a population with a high proportion of African American (AA) patients.Methods: Patients with IPHNC and SPLC treated between 2000 and 2017 were reviewed for demographic, disease, and treatment-related characteristics and compared to age-and-stage-matched controls without SPLC. Logistic and Cox regression models were used to analyze the relationship of these characteristics with the development of SPLC and overall survival (OS).Results: Eighty-seven patients and controls were compared respectively. AA race was associated with a significantly higher risk of developing SPLC (OR 2.92, 95% CI 1.35-6.66). After correcting for immortal time bias, patients with SPLC had a significantly lower OS when compared with controls (HR 0.248, 95% CI 0.170-0.362). Conclusions: We show that AA race is associated with an increased risk of SPLC after IPHNC; reasons of this increased risk warrant further investigation.

show abstract

Performance of Lung-RADS in different target populations: a systematic review and meta-analysis

Mao,

Cai,

Heuvelmans

et al. 2023

Eur Radiol

View full text Add to dashboard Cite

Objectives Multiple lung cancer screening studies reported the performance of Lung CT Screening Reporting and Data System (Lung-RADS), but none systematically evaluated its performance across different populations. This systematic review and meta-analysis aimed to evaluate the performance of Lung-RADS (versions 1.0 and 1.1) for detecting lung cancer in different populations. Methods We performed literature searches in PubMed, Web of Science, Cochrane Library, and Embase databases on October 21, 2022, for studies that evaluated the accuracy of Lung-RADS in lung cancer screening. A bivariate random-effects model was used to estimate pooled sensitivity and specificity, and heterogeneity was explored in stratified and meta-regression analyses. Results A total of 31 studies with 104,224 participants were included. For version 1.0 (27 studies, 95,413 individuals), pooled sensitivity was 0.96 (95% confidence interval [CI]: 0.90–0.99) and pooled specificity was 0.90 (95% CI: 0.87–0.92). Studies in high-risk populations showed higher sensitivity (0.98 [95% CI: 0.92–0.99] vs. 0.84 [95% CI: 0.50–0.96]) and lower specificity (0.87 [95% CI: 0.85–0.88] vs. 0.95 (95% CI: 0.92–0.97]) than studies in general populations. Non-Asian studies tended toward higher sensitivity (0.97 [95% CI: 0.91–0.99] vs. 0.91 [95% CI: 0.67–0.98]) and lower specificity (0.88 [95% CI: 0.85–0.90] vs. 0.93 [95% CI: 0.88–0.96]) than Asian studies. For version 1.1 (4 studies, 8811 individuals), pooled sensitivity was 0.91 (95% CI: 0.83–0.96) and specificity was 0.81 (95% CI: 0.67–0.90). Conclusion Among studies using Lung-RADS version 1.0, considerable heterogeneity in sensitivity and specificity was noted, explained by population type (high risk vs. general), population area (Asia vs. non-Asia), and cancer prevalence. Clinical relevance statement Meta-regression of lung cancer screening studies using Lung-RADS version 1.0 showed considerable heterogeneity in sensitivity and specificity, explained by the different target populations, including high-risk versus general populations, Asian versus non-Asian populations, and populations with different lung cancer prevalence. Key Points • High-risk population studies showed higher sensitivity and lower specificity compared with studies performed in general populations by using Lung-RADS version 1.0. • In non-Asian studies, the diagnostic performance of Lung-RADS version 1.0 tended to be better than in Asian studies. • There are limited studies on the performance of Lung-RADS version 1.1, and evidence is lacking for Asian populations.

show abstract

Lung cancer screening in patients with previous malignancy: Is this cohort at increased risk for malignancy?

Cited by 14 publications

References 34 publications

The Efficacy of 18F-FDG PET/CT and Superparamagnetic Nanoferric Oxide MRI in the Diagnosis of Lung Cancer and the Value of 18F-FDG PET/CT in the Prediction of Lymph Node Metastasis

The Efficacy of 18F-FDG PET/CT and Superparamagnetic Nanoferric Oxide MRI in the Diagnosis of Lung Cancer and the Value of 18F-FDG PET/CT in the Prediction of Lymph Node Metastasis

African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer

Performance of Lung-RADS in different target populations: a systematic review and meta-analysis

Contact Info

Product

Resources

About